EUCTR2010-019883-36-ITActive, not recruitingNot Applicable
A 24 week, randomized, double blind, multicenter, placebocontrolled efficacy, safety, tolerability and PK trial of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- OVARTIS FARMA
- Enrollment
- 55
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Inclusion criteria Patients eligible for inclusion in this study have to fulfill all of the following criteria: 1. Written informed consent must be obtained before any assessment is performed 2. Male or female 18 years of age or older who are unable to bear children and females of child bearing potential not disqualified as per Exclusion Criterion 1 (below) 3. WHO Functional Class II or III 4. 6MWD = 150 m and = 450 m at screening. Distances of two consecutive 6MWTs should be within 15% of one another 5. A current diagnosis of Pulmonary Arterial Hypertension according to the Dana Point 2008 Meeting: WHO Diagnostic Group I, idiopathic or heritable (familial or sporadic) PAH, PAH associated with collagen vascular disease including systemic sclerosis, rheumatoid arthritis, mixed connective tissue diseases, and overlap syndrome. PAH following one year repair of congenital heart defect (ASD, VSD or PDA), or PAH associated with diet therapies or other drugs 6. Inadequate clinical response despite stabilization on one or more class(es) of PAH drug [e.g., PDE5 inhibitor, endothelin receptor blocker, vasodilator prostaglandin (systemic, inhaled or oral)] 7. Stabilization of pulmonary hypertension medications defined as observed for = 2 months on approved therapeutic dose of at least one PAH drug and still symptomatic with WHO functional Class II or III performance.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 55
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Exclusion criteria Patients fulfilling any of the following criteria are not eligible for inclusion in this study: 1. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant. UNLESS they are: ?? women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner ?? women whose partners have been sterilized by vasectomy or other means ?? using two birth control methods. The two methods can be a double barrier method or a barrier method plus a hormonal method. Adequate barrier methods of contraception include: diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or a progestational agent 2. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 10 mIU/mL) 3. History of ventricular tachycardia, ventricular fibrillation or ventricular flutter 4. Use of drugs known to prolong the QT interval or known to be strong CYP3A4 inhibitors (refer to Appendix 6) 5. Untreated or inadequately controlled hypokalemia (<3.5 mmol/L) or hypomagnesemia (<0.65 mmol/L) at the screening visit (Visit 1) 6. Evidence of clinically significant left ventricular dysfunction. 7. Evidence of clinically significant hepatic impairment, including AST or ALT > 3 times the upper limit of normal (if due to bosentan therapy subject is excluded unless bosentan is discontinued and the above LFTs return to < 2 times the upper limit of normal; Subject must still be on a stable regimen including at least one approved PAH therapy at time of study drug randomization). Bilirubin > 2 times the upper limit of normal. [Canada only: AST or ALT > 1.5 times the upper limit of normal] 8. Atrial fibrillation or history of atrial fibrillation in the previous 3 months 9. Having syncope in the 3 months prior to the screening visit 10. History of previous myocardial infarction, unstable angina, or clinically significant bradycardia (<60 bpm and accompanied by clinical symptoms) 11. QRS > 120 ms or > 140 ms in the presence of bundle branch block 12. Current or history of consistently prolonged QTcF (2 or more ECGs in the prior 12 months in the absence of a right bundle branch block or QTcF>450 ms for males and > 470 ms for females at screening); family history of long QT syndrome 13. WHO Class IV 14. History of Torsades de Pointes 15. In treatment with chronic nitric oxide therapy 16. Pre-existing lung disease including parasitic diseases affecting lungs, congenital abnormalities of the lungs, COPD, thorax or diaphragm or bronchial asthma, associated with chronic hypoxia that may contribute to severity of PAH 17. With a pulmonary capillary wedge pressure > 15 mm Hg to rule out PAH secondary to left ventricular dysfunction 18. Diagnosis of pulmonary artery or vein stenosis 19. With other diagnosis of PAH in WHO Diagnostic Group 1 are excluded including congenital systemic to pulmonary shunts (large, small that are not surgically repaired), portal hypertension, HIV infection, glycogen storage disease, Gaucher’s disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders) 20. With a diagnosis of PAH associated with: venous hypertension (WHO Diagnostic Group II), hypoxia (WHO Diagnostic Group III), chronic pulmonary t
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability and PK trial of Nilotinib (Tasigna®, AMN107) in Pulmonary Arterial Hypertension (PAH)Pulmonary Arterial Hypertension (PAH) Class II or III patients remaining symptomatic despite at least one PAH-specific therapy.MedDRA version: 12.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionEUCTR2010-019883-36-HUovartis Pharma AG66
Active, not recruiting
Not Applicable
A 24 week, randomized, double blind, multicenter, placebo-controlled efficacy, safety, tolerability and PK trial of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)Pulmonary Arterial Hypertension (PAH) Class II or III patients remaining symptomatic despite at least one PAH-specific therapy.MedDRA version: 14.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-019883-36-DEovartis Pharma Services AG55
Active, not recruiting
Phase 1
A 24-week study to compare efficacy and safety of oral masitinib to placebo in the treatment of patients with severe mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatmentsevere mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatmentMedDRA version: 20.1Level: PTClassification code 10075217Term: Mast cell activation syndromeSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2021-005406-96-BEAB Science78
Active, not recruiting
Phase 1
A 24-week study to compare efficacy and safety of oral masitinib to placebo in the treatment of patients with severe mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatmentsevere mast cell activation syndrome (MCAS) with handicap unresponsive to optimal symptomatic treatmentMedDRA version: 20.1Level: PTClassification code 10075217Term: Mast cell activation syndromeSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2021-005406-96-DEAB Science78
Active, not recruiting
Phase 1
Study to evaluate safety and efficacy of Dapagliflozin in patients with type 2 diabetes mellitus aged 10-24 yearsEUCTR2015-005041-31-ROAstraZeneca AB70